The class of compounds referred to as Abin-1 inhibitors encompasses a group of chemical agents that are specifically designed to modulate the activity of the Abelson interactor 1 (Abin-1) protein. Abin-1 is a critical regulator of cellular signaling pathways, playing a pivotal role in processes such as cellular adhesion, proliferation, and migration. Abin-1 is particularly noteworthy due to its interaction with the Abl-1 kinase, a key player in various cellular functions. In this context, Abin-1 inhibitors exert their effects by interfering with the interaction between Abin-1 and Abl-1 kinase, leading to downstream effects on various cellular processes. Structurally, Abin-1 inhibitors exhibit a diverse range of chemical compositions. These compounds are meticulously designed to bind to specific sites on Abin-1, disrupting its functional interaction with Abl-1 kinase.
One common mechanism involves the inhibition of Abin-1's ability to associate with Abl-1 through competition for binding sites. This interference subsequently leads to the modulation of the signaling pathways regulated by Abl-1, which are integral to fundamental cellular behaviors. In some cases, Abin-1 inhibitors may operate through allosteric mechanisms, inducing conformational changes in Abin-1 that hinder its interaction with Abl-1 kinase. The development and study of Abin-1 inhibitors hold significant promise for advancing our understanding of cellular signaling cascades and their intricate regulation. By specifically targeting the Abin-1 and Abl-1 interaction, researchers aim to decipher the intricate interplay between these proteins and their downstream effects. This class of inhibitors presents a valuable tool for investigating the mechanistic underpinnings of cellular processes that are intricately associated with Abin-1's functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Binds to the ATP-binding site of Abl-1, inhibiting its kinase activity; used for chronic myeloid leukemia and certain other cancers. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Binds to the ATP-binding site of Abl-1 and other kinases, inhibiting their activity; indicated for various types of leukemia. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Selectively inhibits the kinase activity of Abl-1 by targeting its ATP-binding site; used for chronic myeloid leukemia. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Targets the ATP-binding domain of Abl-1, inhibiting its kinase activity; used for resistant forms of chronic myeloid leukemia. | ||||||
Bcr-abl Inhibitor | 778270-11-4 | sc-203836 | 5 mg | $149.00 | 1 | |
Allosteric inhibitor that binds outside the ATP-binding pocket of Abl-1, causing conformational changes that lead to inhibition. | ||||||